Last reviewed · How we verify
HBV Viral Suppression by Entecavir in Adefovir Partial Responders (ADVPR)
We propose a largely retrospective study with short-term prospective follow-up in a subgroup of patients who have not yet been treated with 48 weeks of entecavir following partial response to adefovir. The aim of the study is to describe sequential virologic response to adefovir and entecavir.
Details
| Lead sponsor | Pacific Health Foundation |
|---|---|
| Status | COMPLETED |
| Enrolment | 60 |
| Start date | 2008-05 |
| Completion | 2011-10 |
Conditions
- Hepatitis B
Interventions
- Entecavir
Primary outcomes
- HBV DNA PCR after 12 weeks of entecavir from the time of medication switching: percent of patients with <2log drop in HBV DNA and percent of patients with complete viral suppression during adefovir versus during entecavir. — 48 weeks or after
Countries
United States